GW Pharma (GWPH) Tops Q1 Revenue, EPS

GW Pharma (NASDAQ: GWPH) reported Q1 EPS of ($0.20), $2.70 better than the analyst estimate of ($2.90). Revenue for the quarter came in at $6.7 million versus the consensus estimate of $5.35 million.

“We are pleased by the high level of physician and patient demand for Epidiolex, and by the number of payors that have already made favorable coverage determinations for the product. With US launch taking place part way through the quarter, the two month selling period at the end of 2018 was primarily aimed at setting the commercial wheels in motion for the 2019 launch year. As we move into the New Year, prescription growth trajectory has been highly encouraging and we believe that we are on track to deliver a successful market introduction of this important new treatment,” stated Justin Gover, GW’s Chief Executive Officer. “In addition to the US launch, we look forward to a positive regulatory decision in Europe in the next few months, results of a Phase 3 trial in Tuberous Sclerosis Complex, and a number of advances in the pipeline.”

For earnings history and earnings-related data on GW Pharma (GWPH) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Newton Golf Company (NWTG) Reports Q2 Loss of $0.49